The European heart valve devices market will grow through 2029, fueled by the rapid adoption of THV devices and an aging population. Clinical investigations continue to generate positive results and propel the THV market forward; large companies, in particular, are vying to secure and expand their market share by launching clinical trials and targeting small companies with innovative devices for acquisition to add new, cutting-edge THV devices to their portfolios. Furthermore, novel devices and device types will continue to emerge in the coming years and access new patient populations, generating continued growth in this market. However, the COVID-19 global pandemic will have a significant impact on the European heart valve devices market, resulting in lost procedure volumes in the short term followed by a period of recovery.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for heart valve devices in Europe across a 10-year period.

New THV technologies, including TTVR and TMVI, are emerging in the European market.

How will the recent approval of TTVR and TMVI devices impact the European heart valve devices market?

Will TMVI and TMVR devices compete for market share?

Will new THV replacement and repair devices experience the same adoption as TAVR devices?

Which companies are developing new THV devices, and which companies will receive approvals first?

When will various transcatheter devices enter the market?

How will new transcatheter technologies affect the surgical repair and replacement device markets?

Surgical heart valve device manufacturers are launching devices that offer improved durability, safety, and efficacy.

How are improvements to surgical heart valve replacement and repair devices impacting market revenues, given rising competition from THV devices?

Which European countries will see the strongest demand for surgical devices?

Market leaders in European heart valve devices are consolidating or capturing sales and improving market shares by acquiring smaller competitors.

Which companies are leading the market and what has contributed to their success?

What technologies are larger players adding to their product portfolios through acquisitions?

The COVID-19 pandemic is having a significant impact on cardiovascular medtech markets.

Which upcoming products and clinical trials will be delayed as a result of the pandemic?

How significantly are heart valve procedure volumes being reduced in the wake of the crisis?

How soon will revenues recover after the impact of the pandemic?

Table of contents

  • Heart Valve Devices - Market Insights - Europe

Author(s): Drew Wallace

Drew C. Wallace is an analyst on the Cardiovascular Medtech Insights team, specializing in heart valve and cardiac rhythm management device markets. Drew holds a Master's degree in Developmental Biology from the University of Western Ontario. Prior to his current position, Drew worked at the Princess Margaret Cancer Centre on the immunotherapy clinical trial program.